10-Q: Forte Biosciences Reports Positive Celiac Data, Boosts Cash

Forte Biosciences announced positive Phase 1b celiac disease trial results for FB102 and significantly strengthened its cash position through recent public offerings.

Summary

• Forte Biosciences, a clinical-stage biopharmaceutical company, reported positive data from its Phase 1b study of FB102 in celiac disease in June 2025.
• The company initiated a Phase 2 celiac study in July 2025, with topline results anticipated in 2026.
• FB102 demonstrated a statistically significant benefit on the composite histological VCIEL endpoint (p=0.0099) and a decline in CD3-positive T cells (p=0.0035) in the Phase 1b celiac trial.
• Gluten challenge induced GI symptoms showed a 42% benefit for FB102-treated subjects compared to placebo.
• Forte Biosciences closed a public offering on June 25, 2025, raising $75.0 million in gross proceeds from the sale of common stock and pre-funded warrants.
• In July 2025, underwriters exercised an option, purchasing an additional 148,258 shares for $1.8 million in gross proceeds.
• Cash and cash equivalents increased significantly to $106.1 million as of June 30, 2025, up from $22.2 million at December 31, 2024.
• The company incurred a net loss of $26.9 million for the six months ended June 30, 2025, compared to $19.9 million for the same period in 2024.
• Research and development expenses increased to $21.3 million for the six months ended June 30, 2025, from $10.1 million in the prior year, driven by clinical trial advancements.
• General and administrative expenses decreased to $6.4 million for the six months ended June 30, 2025, from $10.5 million in the prior year, primarily due to lower legal and professional fees.
• Forte believes its existing cash and cash equivalents are sufficient to fund operations for at least twelve months from the filing date.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the strong clinical data for FB102 in celiac disease and the significant increase in cash reserves from recent capital raises, which extends the company's operational runway. However, the company remains unprofitable with increasing R&D expenses and faces numerous inherent risks associated with clinical-stage biopharmaceutical development, preventing a higher score.

Positives

• Positive Phase 1b clinical trial data for FB102 in celiac disease, showing statistically significant benefits on key histological and inflammatory endpoints (VCIEL p=0.0099, CD3-positive T cells p=0.0035).
• FB102 treatment resulted in a 73% improvement in the Vh:Cd ratio and a 42% reduction in gluten challenge-induced GI symptoms compared to placebo in the celiac study.
• Successful completion of a public offering and subsequent underwriter option exercise, raising a total of $76.8 million in gross proceeds, significantly bolstering the company's cash position.
• Cash and cash equivalents increased to $106.1 million as of June 30, 2025, providing a stronger liquidity runway for at least 12 months.
• Initiation of a Phase 2 celiac study and planned Phase 1b alopecia areata study, indicating active progression of the FB102 pipeline.
• Decrease in general and administrative expenses by $4.1 million for the three months and $4.1 million for the six months ended June 30, 2025, primarily due to reduced legal and professional fees.

Negatives

• Continued and increasing net losses, with a net loss of $26.9 million for the six months ended June 30, 2025, compared to $19.9 million for the same period in 2024.
• Increased cash used in operating activities, rising to $20.4 million for the six months ended June 30, 2025, from $12.6 million in the prior year.
• Accumulated deficit grew to $180.9 million as of June 30, 2025, reflecting ongoing unprofitability.
• Significant dilution for existing shareholders due to recent public offerings and private placements, substantially increasing the number of outstanding shares and warrants.
• The company has no products approved for commercial sale and has not generated any revenue from product sales since inception.

Risks

• Forte will require additional capital to fund its operations and may not be able to complete the development and commercialization of FB102 or future product candidates if financing is not obtained.
• The business is almost entirely dependent on the success of developing FB102, which may not be successful.
• Results from early preclinical studies and clinical trials may not be predictive of results from later-stage studies or clinical trials.
• Forte has a limited operating history and no approved products, making it difficult to evaluate its technology and predict future performance.
• Clinical development is a lengthy, expensive, and uncertain process, potentially leading to additional costs or delays.
• Planned preclinical studies or clinical trials may reveal significant adverse events, inhibiting regulatory approval or market acceptance.
• Interim top-line and preliminary data from clinical trials may change as more patient data become available and are subject to audit and verification.
• Market opportunities for FB102 may be limited, and estimates of target patient populations may be inaccurate.
• Reliance on third parties to conduct preclinical studies, clinical trials, and manufacturing increases risks of unsatisfactory performance or delays.
• The market price of Forte's common stock is expected to be volatile, and past volatility has led to class action securities litigation.
• Potential for material weaknesses in internal control over financial reporting, which could adversely affect investor confidence.
• Operations and financial results could be adversely impacted by public health emergencies or other industry disruptions.
• The company will need to grow its organization and may experience difficulties in managing this growth.
• Loss of key management personnel or failure to recruit additional highly skilled personnel could impair development efforts.
• Internal computer systems or those of third parties may fail or suffer security breaches, leading to loss of sensitive data.
• Employees, contractors, and partners may engage in misconduct or improper activities, including noncompliance with regulatory standards.
• Risks associated with testing and developing product candidates internationally, including differing regulatory requirements and economic instability.
• Lack of a marketing and sales organization, requiring significant capital and time to establish or reliance on third parties.
• Tax reform legislation, such as the One Big Beautiful Bill Act, could adversely affect the business and financial condition.
• Ability to use net operating losses and R&D credits to offset future taxable income may be subject to limitations.
• Unstable market and economic conditions, including adverse developments affecting the financial services industry, may have serious adverse consequences.
• Changes in U.S. trade policy could have a material adverse impact on the business.
• Inability to obtain and maintain patent protection for FB102 could allow competitors to commercialize similar products.
• If the scope of patent protection is not sufficiently broad, or if future patent protection is lost, the ability to prevent competitors would be adversely affected.
• Future issued patents could be found invalid or unenforceable if challenged.
• Patent terms may be inadequate to protect competitive position for an adequate amount of time.
• Failure to obtain patent term extension and/or data exclusivity could materially harm the business.
• Claims challenging the inventorship of patents and other intellectual property may arise.
• Inability to protect the confidentiality of trade secrets would harm the business and competitive position.
• Claims that employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of former employers.
• Third-party claims of intellectual property infringement, misappropriation, or other violation against Forte or its collaborators may prevent or delay development.
• Intellectual property rights do not necessarily address all potential threats.
• Non-compliance with Nasdaq's minimum bid price requirement could result in delisting of common stock.
• Principal stockholders and management own a significant percentage of stock and can exert significant control over matters subject to stockholder approval.
• Anti-takeover provisions in charter documents and Delaware law could make an acquisition more difficult.
• Bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes, limiting stockholders' ability to choose a favorable judicial forum.
• Future sales of shares by existing stockholders could cause the stock price to decline.
• If equity research analysts do not publish research or publish unfavorable reports, stock price and trading volume could decline.
• Broad discretion in the use of proceeds from capital raising efforts, which may not increase the value of investments.

Future Outlook

Management expects to continue incurring additional losses in the foreseeable future as development efforts for FB102 advance through clinical trials. The company believes its existing cash and cash equivalents will fund operations for at least twelve months from the filing date, but additional capital will be needed. Topline data for the Phase 2 celiac study and Phase 1b alopecia areata study are expected in 2026, with Phase 1b non-segmental vitiligo data expected in the first half of 2026. The company is evaluating the impact of the recently enacted One Big Beautiful Bill Act (OBBBA) on its financial statements.

Management Comments

• "We believe that our existing cash and cash equivalents will be sufficient to allow the Company to fund its operations for at least twelve months from the filing date of this Form 10-Q."
• "Management expects to continue to incur additional losses in the foreseeable future as the Company focuses its development efforts on advancing FB102 through clinical trials."
• "The Company will continue to need to raise additional capital or obtain financing from other sources."

Industry Context

Forte Biosciences operates in the highly competitive clinical-stage biopharmaceutical industry, focusing on autoimmune and autoimmune-related indications. The company's lead candidate, FB102, targets celiac disease, non-segmental vitiligo, and alopecia areata, which represent significant market opportunities with unmet needs. For instance, celiac disease affects an estimated 2.5 million people in the U.S. with no approved treatments, while the global vitiligo and alopecia treatment markets are projected to reach $2.3-2.7 billion and $6 billion respectively by 2032-2034. The industry faces macroeconomic challenges including military conflicts, inflation, rising interest rates, and potential financial institution failures. Regulatory changes, such as the U.S. federal government's One Big Beautiful Bill Act and the Supreme Court's overruling of the Chevron doctrine, introduce further uncertainty and potential impacts on tax treatment and regulatory review processes.

Comparison to Industry Standards

• The positive Phase 1b celiac disease data for FB102, particularly the statistically significant histological and inflammatory endpoint benefits, are encouraging for a clinical-stage asset in an area with no approved treatments, suggesting a potentially differentiated mechanism of action compared to other investigational therapies.
• The company's cash runway of at least 12 months, following significant capital raises, is generally in line with or slightly better than many early-to-mid-stage biotech companies, which frequently require substantial funding to advance their pipelines.
• The increased R&D expenses reflect a common trend in the biotech sector as companies progress their lead candidates into later-stage clinical trials, aligning with industry benchmarks for development-stage companies.
• The continued net losses and accumulated deficit are typical for clinical-stage biopharmaceutical companies that have not yet commercialized a product, as significant investment is required for research and development before potential revenue generation.

Corporate Governance

Legal Proceedings

• Forte Biosciences, Inc. v. Wesco Insurance Co., et al., Case No. N24C-10-015 VLM CCLD (Del. Super. Ct.): In October 2024, the company filed a complaint against its current and former Directors & Officers liability insurance carriers (Wesco Insurance Company, Beazley Insurance Company, and Palms Insurance Company, Limited) for declaratory relief, breach of contract, and bad faith. The company alleges the Insurance Defendants refused to provide coverage for previous legal actions, including Camac Fund lawsuits and books and records demands. Forte seeks a declaratory judgment, reimbursement, compensatory damages, and consequential/punitive damages.
• Camac Fund, LP v. Paul A. Wagner, et al., C.A. No. 2023-0817-MTZ (Del. Ch.): Resolved in September 2024 with a $1.5 million payment to Plaintiff's counsel for fees and expenses.
• Forte Biosciences, Inc. v. Camac Fund, LP, et al., Case No. 3:23-cv-02399-N (N.D. Tex.): Resolved in October 2024 through a settlement agreement and release, with the company paying $650 thousand related to these agreements. Certain Texas Defendants also entered into standstill and voting agreements.

Related Party Transactions

• One member of the company's board of directors received $150,000 for scientific consulting services during the three months ended June 30, 2025, and $300,000 for the six months ended June 30, 2025.
• Certain executive officers and senior management participated in the November 2024 Private Placement, purchasing $475,000 in shares of common stock.
• Certain executive officers, senior management, and board members participated in the July 2023 Private Placement, purchasing $1.16 million of shares of common stock.

Stakeholder Impact

• **Shareholders**: Experienced significant dilution from recent public offerings and private placements, but the capital raises provide a longer operational runway and fund ongoing clinical development. Positive Phase 1b celiac data could increase investor confidence in FB102's potential. Ongoing legal proceedings against D&O insurers could impact financial resources if unsuccessful.
• **Employees**: Increased R&D expenses and plans for organizational growth suggest potential for new hires and continued investment in personnel. Stock-based compensation remains a significant component of compensation, tying employee incentives to company performance. The 401(k) plan provides retirement benefits.
• **Customers (future patients)**: Positive Phase 1b data for FB102 in celiac disease and progression to Phase 2 offer hope for a new treatment option in an area with no approved therapies. Development in vitiligo and alopecia areata also addresses significant unmet medical needs.
• **Creditors**: The strengthened cash position from recent capital raises improves the company's short-term financial stability and ability to meet its obligations.
• **Suppliers/CROs/CMOs**: Increased R&D spending indicates continued engagement with third-party vendors for preclinical, clinical, and manufacturing services, providing ongoing business opportunities for these partners.

Next Steps

• Continue patient enrollment for the Phase 1b non-segmental vitiligo trial, with topline data expected in the first half of 2026.
• Initiate a Phase 1b alopecia areata study, with topline data expected in 2026.
• Advance the Phase 2 celiac study, with topline readout expected in 2026.
• Evaluate the impact of the U.S. federal government's One Big Beautiful Bill Act (OBBBA) on condensed consolidated financial statements.
• Monitor for further changes and evaluate enacted provisions of new tax laws and potential impacts.
• Continue to seek additional capital or financing from other sources to fund future operations.

Key Dates

Recommendation

The positive Phase 1b clinical data for FB102 in celiac disease is a significant de-risking event and a strong indicator of potential future success, especially given the lack of approved treatments for the condition. The substantial capital raised through recent offerings provides a crucial liquidity runway, enabling the company to advance its pipeline. However, Forte Biosciences remains a clinical-stage company with no approved products and continues to incur significant operating losses. The path to commercialization is long, expensive, and fraught with regulatory and clinical risks. While the recent news is encouraging, the stock is highly speculative. A 'hold' recommendation acknowledges the positive developments and potential upside but also reflects the inherent high risks and the need for further clinical validation and sustained financial performance before a more aggressive stance is warranted for a seasoned investor.

Keywords

Forte Biosciences, FBRX, Biopharmaceutical, Clinical-stage, FB102, Celiac Disease, Vitiligo, Alopecia Areata, Autoimmune, Monoclonal Antibody, Phase 1b, Phase 2, Clinical Trials, SEC Filing, 10-Q, Financial Results, Capital Raise, Public Offering, Nasdaq